Denali Therapeutics Inc. (DNLI) stock
DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$18.89−0.84 (-4.26%)
Close on Nov 12, 2026Market cap $3.02BP/E –Yield –
Denali Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Denali Therapeutics's enterprise value was $2.44B on Nov 11, 2026, against $2.01B a year earlier. Over the last 5 years it ranged from $1.10B to $4.40B, with a median of $2.34B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $2.44B | +55.3% |
| 2025 | Dec 31, 2025 | $1.57B | -24.9% |
| 2024 | Dec 31, 2024 | $2.09B | +13.0% |
| 2023 | Dec 29, 2023 | $1.85B | -20.7% |
| 2022 | Dec 30, 2022 | $2.34B | -46.9% |
| 2021 | Dec 31, 2021 | $4.40B | -51.5% |
| 2020 | Dec 31, 2020 | $9.07B | +660.6% |
| 2019 | Dec 31, 2019 | $1.19B | -23.9% |
| 2018 | Dec 31, 2018 | $1.57B | +2506.8% |
| 2017 | Dec 29, 2017 | $60.09M | – |
See a number that looks wrong?